

MenQuadfi MenACWY Vaccine Analysis Print.  
All UK spontaneous suspected Adverse Drug Reaction (ADR)  
reports associated with the MenQuadfi MenACWY vaccine up to and including  
14/05/2025.

Report run: 15/05/2025

Earliest reaction date: 07/03/2024

Reaction MedDRA SOC Name	Reaction MedDRA HLGT Name	Reaction MedDRA HLT Name	Reaction MedDRA PT Name	Reaction Total	Fatal
Eye disorders	Ocular infections, irritations and inflammations	Ocular infections, inflammations and associated manifestations	Eye pruritus	1	0
	<b>Total</b>			<b>1</b>	<b>0</b>
Gastrointestinal disorders	Gastrointestinal signs and symptoms	Gastrointestinal and abdominal pains (excl oral and throat)	Abdominal pain	1	0
			Abdominal pain upper	1	0
		Nausea and vomiting symptoms	Nausea	1	0
			Vomiting	2	0
	<b>Total</b>			<b>5</b>	<b>0</b>
General disorders and administration site conditions	Body temperature conditions	Febrile disorders	Pyrexia	3	0
	General system disorders NEC	Asthenic conditions	Asthenia	1	0
			Fatigue	2	0
			Malaise	1	0
	Feelings and sensations NEC		Chills	1	0
			Feeling cold	1	0
	General signs and symptoms NEC		Peripheral swelling	2	0
			Swelling	1	0
	Pain and discomfort NEC		Pain	1	0
	<b>Total</b>			<b>13</b>	<b>0</b>
Immune system disorders	Allergic conditions	Anaphylactic and anaphylactoid responses	Anaphylactic reaction	1	0
	<b>Total</b>			<b>1</b>	<b>0</b>
Infections and infestations	Viral infectious disorders	Herpes viral infections	Herpes zoster	1	0
	<b>Total</b>			<b>1</b>	<b>0</b>
Investigations	Cardiac and vascular investigations (excl enzyme tests)	Heart rate and pulse investigations	Heart rate decreased	1	0
	Metabolic, nutritional and blood gas investigations	Carbohydrate tolerance analyses (incl diabetes)	Blood glucose increased	1	0
	<b>Total</b>			<b>2</b>	<b>0</b>
Metabolism and nutrition disorders	Glucose metabolism disorders (incl diabetes mellitus)	Hyperglycaemic conditions NEC	Insulin resistance	1	0
	<b>Total</b>			<b>1</b>	<b>0</b>
Musculoskeletal and connective tissue disorders	Muscle disorders	Muscle pains	Myalgia	1	0
	<b>Total</b>			<b>1</b>	<b>0</b>
Nervous system disorders	Headaches	Headaches NEC	Headache	4	0
	Movement disorders (incl parkinsonism)	Tremor (excl congenital)	Tremor	1	0
	Neurological disorders NEC	Neurological signs and symptoms NEC	Dizziness postural	1	0
			Paraesthesias and dysaesthesias	1	0
	Seizures (incl subtypes)	Seizures and seizure disorders NEC	Seizure	1	0
	Sleep disturbances (incl subtypes)	Narcolepsy and hypersomnia	Hypersomnia	1	0
	<b>Total</b>			<b>9</b>	<b>0</b>
Respiratory, thoracic and mediastinal disorders	Bronchial disorders (excl neoplasms)	Bronchial conditions NEC	Bronchial secretion retention	1	0
	Respiratory disorders NEC	Breathing abnormalities	Dyspnoea	1	0
	Respiratory tract signs and symptoms	Upper respiratory tract signs and symptoms	Rhinorrhoea	1	0
	<b>Total</b>			<b>3</b>	<b>0</b>
Skin and subcutaneous tissue disorders	Angioedema and urticaria	Urticarias	Urticaria	1	0
	Epidermal and dermal conditions	Rashes, eruptions and exanthems NEC	Rash	1	0
			Rash pruritic	1	0
	Skin appendage conditions	Apocrine and eccrine gland disorders	Hyperhidrosis	1	0
	Skin vascular abnormalities	Purpura and related conditions	Henoch-Schonlein purpura	1	0
	<b>Total</b>			<b>5</b>	<b>0</b>
Vascular disorders	Decreased and nonspecific blood pressure disorders and shock	Circulatory collapse and shock	Circulatory collapse	1	0
		Vascular hypotensive disorders	Hypotension	1	0
	Vascular disorders NEC	Peripheral vascular disorders NEC	Cyanosis	1	0
	<b>Total</b>			<b>3</b>	<b>0</b>
<b>TOTAL REACTIONS FOR DRUG</b>				<b>45</b>	
<b>TOTAL REPORTS</b>				<b>13</b>	
<b>TOTAL FATAL OUTCOME REPORTS</b>					<b>0</b>